Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

Anurag Mehta; Arjun Gupta; Franck Hannallah; Thomas Koshy; Sharon Reimold

doi:10.1097/CMR.0000000000000251

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

Anurag Mehta
, Arjun Gupta
, Franck Hannallah
, Thomas Koshy
, Sharon Reimold

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	319-320
Number of pages	2
Journal	Melanoma research
Volume	26
Issue number	3
DOIs	https://doi.org/10.1097/CMR.0000000000000251
State	Published - 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/CMR.0000000000000251

Find It

Find It at U of M Libraries

Cite this

@article{bab6254c5b1e48f3b56b9a4a86d67152,

title = "Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma",

author = "Anurag Mehta and Arjun Gupta and Franck Hannallah and Thomas Koshy and Sharon Reimold",

year = "2016",

doi = "10.1097/CMR.0000000000000251",

language = "English (US)",

volume = "26",

pages = "319--320",

journal = "Melanoma research",

issn = "0960-8931",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

AU - Mehta, Anurag

AU - Gupta, Arjun

AU - Hannallah, Franck

AU - Koshy, Thomas

AU - Reimold, Sharon

PY - 2016

Y1 - 2016

UR - https://www.scopus.com/pages/publications/84966589355

UR - https://www.scopus.com/pages/publications/84966589355#tab=citedBy

U2 - 10.1097/CMR.0000000000000251

DO - 10.1097/CMR.0000000000000251

M3 - Letter

C2 - 27110676

AN - SCOPUS:84966589355

SN - 0960-8931

VL - 26

SP - 319

EP - 320

JO - Melanoma research

JF - Melanoma research

IS - 3

ER -

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

UN SDGs

Publisher link

Find It

Other files and links

Cite this